A series of structurally novel proteasome inhibitors 1-12 have been developed based rational topology-based scaffold hopping of bortezomib. Among these novel proteasome inhibitors, compound 10 represents an important advance due to the comparable proteasome-inhibitory activity (IC = 9.7 nM) to bortezomib (IC = 8.3 nM), the remarkably higher BEI and SEI values and the effectiveness in metabolic stability. Therefore, compound 10 provides an excellent lead suitable for further optimization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2018.05.018 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!